Beginning in 2012, Heffter funded a successful pilot trial with psilocybin for the treatment of alcoholism at the University of New Mexico. This 10 participant study showed highly significant improvements in alcohol use and life-satisfaction after two psilocybin sessions. Currently, at New York University, Michael Bogenschutz, M.D. and his team are conducting a follow-up clinical trial of 180 patients with alcohol-specific psychotherapy for alcohol dependence and two sessions with psilocybin or placebo. The study is expected to finish in 2019 and continues to seek funding.
At Johns Hopkins University, Matt Johnson, Ph.D. and his team piloted a trial with 15 participants, 80% of whom remained abstinent after three sessions with psilocybin. The team is currently conducting a placebo-controlled clinical trial of 80 participants with nicotine dependence, with half receiving psilocybin and half receiving nicotine patch treatment. All subjects receive specific psychotherapy for smoking cessation and a single psilocybin session. In addition, subjects will receive fMRI neuroimaging through government funding to help understand the neurobiological changes that occur when psilocybin is administered to smokers. The study is expected to finish in 2017.
At the University of Alabama, Birmingham, Peter Hendricks, Ph.D. and his team are conducting a placebo-controlled pilot study of 40 patients with cocaine dependence, with half receiving psilocybin and half an active placebo, and all will receive specific psychotherapy for cocaine dependence and fMRI neuroimaging before and after psilocybin treatment. Heffter provided seed funding for this project, which is also funded by the University.
Sarah - UNM Alcohol Dependence Study
Sarah describes her experience of becoming sober from alcohol dependence with psilocybin treatment at the University of New Mexico. This is the first psychedelic treatment for alcohol dependence in about 50 years.
Sarah - UNM Alcohol Dependence Study - longer video
An extended version of Sarah's video interview of her two psilocybin sessions and the results she experienced.
Stephen Ross, M.D.
Stephen Ross, M.D. discusses Psilocybin, Addiction, and End of Life.
Hallucinogens Could Hold Key To Quitting Smoking
For cigarette smokers, quitting can be an incredibly challenging experience. Approximately 480,000 Americans die every year from cigarettes, making it the single largest preventable cause of disease and death in the country...Read more
Current Drug Abuse Reviews
At the end of last month we published the first part of a special issue on the beneficial effects of psychedelics in the treatment of addiction of the scientific journal CDAR...Read more
Psychedelic therapy may become available in a decade
Matthew Johnson is part of the team at the Johns Hopkins University that conducts research with psilocybin in a growing number of areas, ranging from mystical experiences to the treatment of end-of-life anxiety and addictions...Read more
#14Days: Psilocybin, where science meets spirituality
The future may hold a surprising new approach to treating addiction: using one mind-altering drug to stop the abuse of another...Read more
Magic Mushrooms Help Smokers Kick Habit in Small Study
Just two or three experiences with the hallucinogenic drug known as magic mushrooms helped a dozen long-term smokers quit, succeeding in a study where numerous other approaches failed...Read more